Plasma cell leukemia: definition, presentation, and treatment
MT Gundesen, T Lund, HEH Moeller… - Current oncology …, 2019 - Springer
Abstract Purpose of Review We discuss current topics on the definition of plasma cell
leukemia and the distinction between plasma cell leukemia and multiple myeloma …
leukemia and the distinction between plasma cell leukemia and multiple myeloma …
[HTML][HTML] European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
J Caers, L Garderet, KM Kortüm, ME O'Dwyer… - …, 2018 - ncbi.nlm.nih.gov
The diagnosis of multiple myeloma can be challenging, even for experienced physicians,
and requires close collaboration between numerous disciplines (orthopedics, radiology …
and requires close collaboration between numerous disciplines (orthopedics, radiology …
ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma
Amplification of 1q21 occurs in approximately 30% of de novo and 70% of relapsed multiple
myeloma (MM) and is correlated with disease progression and drug resistance. Here, we …
myeloma (MM) and is correlated with disease progression and drug resistance. Here, we …
[HTML][HTML] IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
PJ Teoh, TH Chung, PYZ Chng, SHM Toh… - …, 2020 - ncbi.nlm.nih.gov
Abstract 1q21 amplification is an important prognostic marker in multiple myeloma. In this
study we identified that IL6R (the interleukin-6 membrane receptor) and ADAR1 (an RNA …
study we identified that IL6R (the interleukin-6 membrane receptor) and ADAR1 (an RNA …
The importance of fish signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: is it underestimated?
L Gao, Y Liu, Y Li, L Feng, Z Wang, L Wen… - … Myeloma and Leukemia, 2022 - Elsevier
Background The cut-off value for gain/amplification of 1q21 (1q21+) was 20% according to
the recommendations of the European Myeloma Network and there were limited studies …
the recommendations of the European Myeloma Network and there were limited studies …
[HTML][HTML] 1q21 扩增对硼替佐米治疗初治多发性骨髓瘤患者疗效和预后的影响
刘雪莲， 杨珮钰， 于小源， 陈敬成， 刘晓亮… - Chinese Journal of …, 2018 - ncbi.nlm.nih.gov
1q21扩增对硼替佐米治疗初治多发性骨髓瘤患者疗效和预后的影响- PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …
ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells
Y Kazuma, K Shirakawa, Y Tashiro, H Yamazaki… - Scientific Reports, 2022 - nature.com
Abstract DNA cytosine deaminase APOBEC3B (A3B) is an endogenous source of mutations
in many human cancers, including multiple myeloma. A3B proteins form catalytically inactive …
in many human cancers, including multiple myeloma. A3B proteins form catalytically inactive …
[PDF][PDF] 1q21 扩增对于初治多发性骨髓瘤预后影响的异质性分析
杨玉， 林彩芹， 李春雨， 戴文露， 武家庆， 李德鹏… - 临床血液学 …, 2021 - lcxy.whuhzzs.com
目的: 探讨1q21 扩增(简称1q) 对于初治多发性骨髓瘤(NDMM) 预后的影响. 方法:
回顾性分析2014 年1 月—2020 年8 月在徐州医科大学附属医院行FISH 检测并规范治疗的171 …
回顾性分析2014 年1 月—2020 年8 月在徐州医科大学附属医院行FISH 检测并规范治疗的171 …
Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH)
A Daudignon, W Cuccuini, C Bracquemart… - Current Research in …, 2023 - Elsevier
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells
(PCs) in the bone marrow. Despite considerable advances in the treatment, MM is …
(PCs) in the bone marrow. Despite considerable advances in the treatment, MM is …
Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH)
[3] Dimopoulos M., Terpos E., Comenzo RL, Tosi P., Beksac M., Sezer O. International
myeloma working group consensus statement and guidelines regarding the current role of …
myeloma working group consensus statement and guidelines regarding the current role of …